Clinical Read2026-06-30

ENHERTU (trastuzumab deruxtecan) - (DESTINY-Lung04)

AstraZeneca PLCAZN
Indication
Non-squamous non-small cell lung cancer (NSCLC)
Stage
phase3
Event
Topline Data
Details

29 April 2026: Q1 2026 clinical trials appendix/pipeline update lists key upcoming pipeline catalysts (2026–2027), recent Phase progressions, and multiple late-stage data readouts/decisions across oncology, biopharma, and rare disease programs.

Key readouts reported (results):

  • Calquence: AMPLIFY (1L CLL fixed-duration) and ECHO (1L MCL) Phase III primary endpoints met (data readouts Q3 2024 and Q2 2024).
  • Datroway (datopotamab deruxtecan): TROPION-Breast02 (metastatic TNBC not candidates for IO) dual primary endpoints met (readout Q4 2025).
  • Enhertu: DESTINY-Breast05 (high-risk HER2+ early breast cancer) primary endpoint met (Q3 2025); DESTINY-Breast09 primary endpoint met for Enhertu+pertuzumab arm (Q2 2025); DESTINY-Breast11 primary endpoint met (Q2 2025).
  • Imfinzi: EMERALD-1 and EMERALD-3 met primary endpoints; PACIFIC-5 met primary endpoint; MATTERHORN met primary endpoint; SAMETA primary endpoint not met.
  • Truqap: CAPItello-281 primary endpoint met (Q4 2024).
  • Baxdrostat: Bax24, BaxAsia, and BaxHTN Phase III primary endpoints met (readouts Q4 2025, Q1 2026, Q3 2025).
  • Breztri: KALOS/LOGOS (uncontrolled asthma) primary endpoints met; ATHLOS (COPD exercise test) primary endpoint met.
  • Tozorakimab: OBERON/TITANIA/MIRANDA (COPD) primary endpoints met; PROSPERO primary endpoint not met.
  • Ultomiris: I CAN (IgA nephropathy) primary endpoint met (Q1 2026); TMA-314 positive high-level results; SANCTUARY met primary endpoint in IgAN cohort but not LN cohort.
  • Anselamimab (CAEL-101): CARES-301 and CARES-302 primary endpoints not met (Q3 2025).
  • Efzimfotase alfa: CHESTNUT and MULBERRY primary endpoints met; HICKORY primary endpoint not met (all readout Q1 2026).
  • Enebo­paratide: CALYPSO primary endpoint met (Q1 2025).
  • Gefurulimab: ALXN1720-MG-301 primary endpoint met (Q3 2025).
  • Elecoglipron: SOLSTICE (T2D) and VISTA (obesity) Phase IIb primary endpoints met (Q1 2026).

Upcoming catalysts (examples named with timing): AVANZAR (1L NSCLC) data anticipated H2 2026; TROPION-Lung15 data anticipated H2 2026; PACIFIC-9 data anticipated H2 2026; EMERALD-2 data anticipated H2 2026; CARDIO-TTRansform (Wainua in ATTR-CM) anticipated H2 2026; DESTINY-Lung04 anticipated H1 2026; VOLGA and NILE anticipated H1 2026; CLARITY-Gastric01 anticipated H2 2026.